SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-22-024422
Filing Date
2022-08-30
Accepted
2022-08-30 17:23:23
Documents
12
Period of Report
2022-08-24
Items
Item 1.01: Entry into a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 37319
  Complete submission text file 0001493152-22-024422.txt   210116

Data Files

Seq Description Document Type Size
2 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT gtbp-20220824.xsd EX-101.SCH 2968
3 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT gtbp-20220824_lab.xml EX-101.LAB 34240
4 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT gtbp-20220824_pre.xml EX-101.PRE 22365
6 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3591
Mailing Address 8000 MARINA BLVD SUITE 100 BRISBANE CA 94005
Business Address 8000 MARINA BLVD SUITE 100 BRISBANE CA 94005 (800) 304-9888
GT Biopharma, Inc. (Filer) CIK: 0000109657 (see all company filings)

IRS No.: 941620407 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40023 | Film No.: 221215477
SIC: 2834 Pharmaceutical Preparations